한글목차

세계의 진행성 핵상성 마비 치료 시장은 2030년까지 1,910만 달러에 달할 전망

2023년에 1,360만 달러로 추정되는 세계의 진행성 핵상성 마비 치료 시장은 분석 기간인 2023-2030년에 CAGR 5.0%로 성장하며, 2030년에는 1,910만 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 약물 요법은 CAGR 6.1%를 기록하며, 분석 기간 종료시에는 870만 달러에 달할 것으로 예측됩니다. 물리 치료 분야의 성장률은 분석 기간 중 CAGR 4.7%로 추정됩니다.

미국 시장은 360만 달러로 추정, 중국은 CAGR 4.7%로 성장 예측

미국의 진행성 핵상성 마비 치료 시장은 2023년에 360만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2023-2030년 CAGR 4.7%로 성장하며, 2030년에는 300만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.6%와 4.0%로 예측됩니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

주요 동향과 촉진요인

진행성 핵상성 마비(PSP)는 운동, 보행(보행) 및 평형 조절, 언어, 삼킴, 시각, 기분과 행동, 인지 능력에 영향을 미치는 희귀한 신경 퇴행성 질환입니다. 뇌의 특정 부위, 주로 신체 움직임과 인지 기능을 담당하는 부위의 뇌세포가 퇴화되어 발생합니다. 가장 특징적인 증상은 보행시 균형이 깨지고 안구 운동, 특히 위나 아래를 보는 데 어려움을 겪습니다. 이러한 증상은 점차 악화되어 연하 장애로 인해 폐렴과 같은 생명을 위협하는 합병증을 유발하는 경우가 많습니다. 현재 PSP를 치료할 수 있는 방법은 없으며, 삶의 질을 향상시키기 위해 증상을 관리하는 것이 치료의 핵심입니다. 이러한 관리에는 증상 완화를 위한 약물 치료, 운동 능력을 향상시키고 낙상을 예방하기 위한 물리치료, 의사소통 문제를 해결하기 위한 언어 치료 등이 포함됩니다.

PSP 치료의 연구개발은 현재도 진행 중이며, 여러 가지 혁신적인 접근법이 연구되고 있습니다. 약리학 연구는 주로 질병의 진행을 늦추거나 증상을 완화하는 것을 목표로 하는 신경 보호 약물과 질병 변형 약물에 초점을 맞추었습니다. 그 중 가장 유망한 것은 타우 단백질 응집 억제제입니다. 타우의 비정상적인 축적은 PSP의 특징입니다. 뇌심부자극요법, 신경외과적 치료 등 비약리학적 치료도 검토되고 있지만 아직 연구 초기 단계이며, PSP의 복잡한 증상으로 인해 신경과 의사, 물리치료사, 언어치료사, 작업치료사 등이 참여하는 다학제적 치료가 점점 더 많이 채택되고 있습니다. 환자가 경험하는 다양한 증상에 대응할 수 있도록 설계되어 있습니다.

진행성 핵상 마비 시장의 성장은 전 세계에서 고령화에 따른 신경 퇴행성 질환의 유병률 증가, 보다 효과적인 치료법에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 또한 진단 기술의 발전으로 PSP를 보다 빠르고 정확하게 진단할 수 있게 되면서 치료 대상이 되는 환자 수가 증가하고 있는 것도 큰 기여를 하고 있습니다. 생명공학 및 제약회사들이 PSP 치료법 및 보다 효과적인 치료법을 찾기 위한 연구개발에 대한 투자를 늘리고 있는 것도 주요 촉진요인 중 하나입니다. 희귀질환에 대한 인식과 옹호활동 증가는 세제 혜택, 보조금, 신약의 조기 승인 등 인센티브를 포함한 규제 당국의 지원 환경도 조성하고 있습니다. 또한 환자 옹호 운동 증가는 맞춤형 헬스케어 솔루션의 필요성을 강조하며 시장 수요와 현재 진행 중인 임상 연구의 초점 모두에 영향을 미치고 있습니다. 이러한 요인들이 결합되어 치료 접근법의 발전과 PSP 시장 개척을 촉진하여 환자의 예후를 개선하고 치료 가능성을 확대할 것으로 기대됩니다.

조사 대상 기업의 예(총 86건)

• AbbVie, Inc.
• AC Immune SA
• Alzprotect
• Amylyx Pharmaceuticals
• Asahi Kasei Pharma Corporation
• Asceneuron
• Biogen, Inc.
• Grupo Ferrer Internacional, S.A.
• Oncolys BioPharma
• Retrotope
• TauRx Pharmaceuticals Ltd.
• Transposon Therapeutics, Inc.
• UCB SA
• Woolsey Pharmaceuticals

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Progressive Supranuclear Palsy Treatment Market to Reach US$19.1 Million by 2030

The global market for Progressive Supranuclear Palsy Treatment estimated at US$13.6 Million in the year 2023, is expected to reach US$19.1 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Pharmacological Therapy, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$8.7 Million by the end of the analysis period. Growth in the Physical Therapy segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Million While China is Forecast to Grow at 4.7% CAGR

The Progressive Supranuclear Palsy Treatment market in the U.S. is estimated at US$3.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Key Trends and Drivers

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder that affects movement, control of walking (gait) and balance, speech, swallowing, vision, mood and behavior, and cognitive abilities. It arises due to the deterioration of brain cells in specific areas of the brain, primarily those that control the body's movements and cognitive functions. The most distinctive symptom, which often results in early misdiagnosis, involves a loss of balance while walking and difficulty managing eye movements, specifically in looking up and down. These symptoms progressively worsen, often leading to life-threatening complications such as pneumonia, due to swallowing difficulties. Currently, there is no cure for PSP, and treatments focus on managing symptoms to improve quality of life. This management can involve medication to reduce symptoms, physical therapy to enhance mobility and prevent falls, and speech therapy to address communication challenges.

Research and development within the field of PSP treatment are ongoing, with several innovative approaches under investigation. Pharmacological research primarily focuses on neuroprotective and disease-modifying drugs that aim to slow the progression of the disease or alleviate its symptoms. Most promising among these are tau protein aggregation inhibitors, as abnormal accumulation of tau is a hallmark of PSP. Non-pharmacological interventions are also being explored, such as deep brain stimulation and other neurosurgical options, though these are still in the early stages of research. Given the complexity of PSP symptoms, multidisciplinary care approaches are increasingly adopted, involving neurologists, physical therapists, speech therapists, and occupational therapists, designed to address the broad spectrum of symptoms experienced by patients.

The growth in the Progressive Supranuclear Palsy market is driven by several factors, including the increasing prevalence of neurodegenerative disorders with aging populations globally, which heightens the demand for more effective treatments. Advances in diagnostic technologies have also significantly contributed, allowing for earlier and more accurate diagnosis of PSP, thereby increasing the number of individuals eligible for treatment. Another key driver is the rising investment in research and development by biotech and pharmaceutical companies aimed at finding a cure or more effective management options for PSP. Enhanced awareness and advocacy for rare disorders have also fostered a supportive regulatory environment that often includes incentives like tax breaks, funding grants, and fast-track approvals for novel therapies. Furthermore, growing patient advocacy movements are emphasizing the need for tailored healthcare solutions, influencing both market demand and the focus of ongoing clinical research. These factors collectively stimulate advancements in treatment approaches and the development of the PSP market, promising improved patient outcomes and expanded therapeutic possibilities.

Select Competitors (Total 86 Featured) -

• AbbVie, Inc.
• AC Immune SA
• Alzprotect
• Amylyx Pharmaceuticals
• Asahi Kasei Pharma Corporation
• Asceneuron
• Biogen, Inc.
• Grupo Ferrer Internacional, S.A.
• Oncolys BioPharma
• Retrotope
• TauRx Pharmaceuticals Ltd.
• Transposon Therapeutics, Inc.
• UCB SA
• Woolsey Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Progressive Supranuclear Palsy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Awareness and Diagnosis Rates of Progressive Supranuclear Palsy
  • Advances in Neuroimaging Technologies Enhancing Diagnostic Accuracy
  • Emerging Biomarkers for Early and Accurate Diagnosis
  • Development of Disease-Modifying Therapies
  • Impact of Genetic Research on Treatment Approaches
  • Increased Funding for Rare Neurodegenerative Disorders
  • Government Initiatives Supporting Neurological Research
  • Expansion of Targeted Therapy and Personalized Medicine
  • Innovations in Drug Delivery Systems
  • Integration of AI and Machine Learning in Drug Development
  • Challenges in Clinical Trial Recruitment
  • Global Health Aging Populations Increasing Prevalence
  • Neuroprotective Treatment Approaches Gaining Traction
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Progressive Supranuclear Palsy Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Progressive Supranuclear Palsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Physical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Speech Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Speech Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Speech Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Symptomatic Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Symptomatic Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Symptomatic Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 19: USA 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Canada Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 22: Canada 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• JAPAN
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Japan Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 25: Japan 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• CHINA
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 27: China Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 28: China 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• EUROPE
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Progressive Supranuclear Palsy Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• FRANCE
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 36: France Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 37: France 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• GERMANY
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Germany Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 40: Germany 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Italy Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 43: Italy 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 45: UK Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 46: UK 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of Europe Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Asia-Pacific Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 52: Asia-Pacific 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Rest of World Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 55: Rest of World 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030

IV. COMPETITION